GNS Healthcare said this week that it has signed a subcontract with SAIC-Frederick to create in silico simulations of drug interaction data generated by applying several well-known cancer treatments to the National Cancer Institute's NCI-60 cancer cell line panel.
Financial terms of the agreement were not disclosed.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
